Isavuconazole - Astellas Pharma
Alternative Names: BAL 4815; RO 00 94815Latest Information Update: 04 Sep 2024
At a glance
- Originator Basilea Pharmaceutica
- Developer Astellas Pharma; Basilea Pharmaceutica
- Class Antifungals; Benzonitrile; Pyridines; Small molecules; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Aspergillosis; Mycoses
Most Recent Events
- 04 Sep 2024 Discontinued - Phase-I for Mycoses (In volunteers) in China (IV)
- 11 Jun 2024 Shanghai Children's Medical Center plans a pharmacokinetic trial in Aspergillosis and Mycoses (In neonates, In infants, In children, In adolescents) in July 2024 (NCT06440915)
- 08 Dec 2023 Registered for Aspergillosis (In children) in USA (IV)